Clemastine: Clinical Trials

10 trials of Clemastine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 recruiting, 2 not yet recruiting. 10 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Completed 4, Recruiting 4, Not yet recruiting 2
Phase 13Recruiting 2, Not yet recruiting 1

Follow Clemastine: new trials by email Literature Review of Clemastine trials Research Report on Clemastine

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy
Clemastine Fumarate, Placebo - Demyelinating Diseases, Demyelination; Corpus Callosum
Phase 1 / Phase 2Not yet recruitingUniversity of California, San Francisco442026-09-152026-03-11
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
Clemastine Fumarate, Placebo - Depression
Phase 2RecruitingUniversity of Illinois at Chicago802025-12-102026-06-30
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially)
Phase 1 / Phase 2RecruitingUniversity of Colorado, Denver3442025-03-312026-04-30
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity
clemastine (8 mg/day), Placebo - Schizophrenia
Phase 2Not yet recruitingLMU Klinikum902024-04-012024-03-20
Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome
Clemastine Fumarate Tablets, corn starch tablets - Williams Syndrome, Child
Phase 2CompletedQilu Hospital of Shandong University282024-03-202026-03-19
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Clemastine Fumarate, Placebo - Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting
Phase 1 / Phase 2RecruitingUniversity of California, San Francisco742023-08-012026-07-02
CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
Metformin and clemastine in combination, Placebo - Multiple Sclerosis
Phase 2CompletedCambridge University Hospitals NHS Foundation Trust702022-03-082025-12-11
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
Clemastine, Placebo - Optic Neuritis
Phase 2RecruitingUniversity of California, San Francisco902017-02-282026-03-11
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
Clemastine, Placebo - Multiple Sclerosis, Relapsing-Remitting
Phase 2CompletedUniversity of California, San Francisco502014-01-012025-09-17
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Omalizumab 75-375 mg, Placebo to omalizumab, Loratadine - Chronic Urticaria
Phase 2CompletedNovartis492007-05-012011-10-21

Conditions studied

Multiple Sclerosis (3)  ·  Multiple Sclerosis, Relapsing-Remitting (2)  ·  Auditory Diseases, Central (1)  ·  Chronic Urticaria (1)  ·  Demyelinating Diseases (1)  ·  Depression (1)  ·  Epilepsy, Idiopathic Generalized (1)  ·  Eye Pain (1)  ·  Hearing Disorders (1)  ·  Hearing Loss (1)  ·  Hearing Loss, Hidden (1)  ·  Hearing Loss, Noise-Induced (1)  ·  Hearing Loss, Sensorineural (1)  ·  Language Development Disorders (1)  ·  Marchiafava-Bignami Disease (1)

Sponsors

University of California, San Francisco (4)  ·  Cambridge University Hospitals NHS Foundation Trust (1)  ·  LMU Klinikum (1)  ·  Novartis (1)  ·  Qilu Hospital of Shandong University (1)  ·  University of Colorado, Denver (1)  ·  University of Illinois at Chicago (1)

Countries

United States (6)  ·  China (1)  ·  Germany (1)  ·  United Kingdom (1)

Top investigators

Achim Klug, PhD (1)  ·  Ari Green, MD, MCR (1)  ·  Ari J Green, MD (1)  ·  Ari J Green, MD, MCR (1)  ·  Ari J. Green, MD, MCR (1)  ·  Nick Cunniffe (1)  ·  Samuel A Budoff, PhD, MS (1)

Results publications

PMID 29029896, PMID 35710320, PMID 41361285